WE STAY FOCUSED ON NEWSWIRE June 15th. Again, I pick up my gratitude rock for having my money in great management keeping investors informed. Good or not so good (lol) news, these newswires are constructed from HARD WORK!
Few investors actually follow the story and do the deep dd in the penny stocks they are invested in.....truth. WE only want good news and we only want sp to go up...dat's da nature of the beast.
Pharna investments were in the dark for decades!! Trump even elimated the bio terror team from administration.
Correction: the headline of this fact-check earlier read “Trump fired pandemic response team in 2018”, it has been amended to “Trump fired entire pandemic response team in 2018”
Before COVID was released into the world to control population and to ease the strain on $ystems $$ caring for them, hardly a SINGLE light was turned on in labratories far n wide. Pharma had no love for a loooooong time.
When covid hit...KABOOOOM BANG BOOOM.........the pharma industry lit up the sky, every light, every microscoope, every blood spinner was a SPINNING.......24/7.
The BIG RACE to find a covid vaccine was on........Trillions$$$$$$ government spending and the BIG winner BILL GATES and his croonies
Bio pharma industry around the world and please do not forget to include the magic mushroom PSILOCYBIN bio sector......is full throttle in HIGH GEAR........currently!!!
Mark it down bio investors!!!
This morning we observe the reaction from this newswire.
hmmmmmmmm BIOV LEVEL 2 is naked on the Ask up to @24 and the Bid is thin down to @11-12, BUT WE HAVE A LOT more buyers on the bid than we do on the ask! NICE to see, NOBODY RUSHING FOR THE DOOR.
sheesh ya gotta ask yourself if our share price licked @25 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! yesterday with todays newswire....WTF is going to happen when we cross milestone....FDA APPROVAL.......that does not count all the other irons of future reveues that we have yet to cross over!!
Stay focused we are waiting on FDA approval by @newswire on 15 Jun 2022, 08:01 Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development
VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production of the Company's ovarian cancer vaccine.
BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used by BioVaxys' Lyon-based manufacturing partner, BioElpida ("BioElpida"), to validate the tumor collection protocol, cryopackaging, cryopreservation, and supply chain logistics for BVX-0918 bioproduction for prospective patients in the US and EU.
Donors of ovarian cancer tumors are required to sign a patient consent form, with the tumor extraction, storage, and shipping logistics following a strict protocol developed by Biovaxys, and subjected to institutional and regulatory approval.
BVX-0918 produced from the surgically removed tumor cells from HCL will be screened using the identity assays derived from the OVCAR-3 cell line recently completed by BioElpida. The identity assay will be performed on every batch of autologous ovarian cancer vaccine, and is mandatory for regulatory bodies in the EU and United States.
BioVaxys President and Chief Operating Officer Kenneth Kovan stated that, "The production of BVX-0918 is a process that built on the prior successful execution of sequential steps, such as the bioproduction technology transfer to BioElpida, development of validation procedures needed to support GMP manufacturing, sterility testing for transport, hapten fixation, cryopreservation methods, antibody generation, bioburden screening, endotoxin assays, and most recently, the development of the identity assays from the OVCAR-3 cell line. With the surgically excised tumors we can now begin the final stages of the vaccine production protocol and GMP validation."
BioVaxys' vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys' cancer vaccines are created by extracting a patient's own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors.
A first generation single-hapten vaccine invented by BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, achieved positive immunological and clinical results in Phase I and Phase II human trials in over 600 patients with different tumor types, as well as having no observed toxicity in years of clinical study. These studies were conducted under an FDA-reviewed IND. A first generation autologous, haptenized vaccine was also tested by Dr. Berd in women with advanced ovarian cancer who had ceased to respond to conventional chemotherapy. The results were encouraging: In 24 patients, the median overall survival was 25.4 months with a range of 4.5-57.4 months; 8 patients survived for more than 2 years. BioVaxys has enhanced the first-generation approach by utilizing two haptens ("bi-haptenization"), which the Company believes will yield superior results.